Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Obesity

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    November 2021
  1. LAU DCW, Erichsen L, Francisco AM, Satylganova A, et al
    Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
    Lancet. 2021 Nov 16. pii: S0140-6736(21)01751.
    PubMed     Abstract available


  2. ABU DAYYEH BK, Maselli DB, Rapaka B, Lavin T, et al
    Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02394.
    PubMed     Abstract available


  3. SUDLOW A, le Roux CW
    Improving gastric balloons to treat obesity.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02505.
    PubMed    


    September 2021
  4. LINGVAY I, Sumithran P, Cohen RV, le Roux CW, et al
    Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.
    Lancet. 2021 Sep 30. pii: S0140-6736(21)01919.
    PubMed     Abstract available


    August 2021
  5. MEGHJI J, Mortimer K, Jayasooriya S, Marks GB, et al
    Lung health in LMICs: tackling challenges ahead - Authors' reply.
    Lancet. 2021;398:490.
    PubMed    


  6. NEMERY B, Katoto PDMC, Develtere P
    Lung health in LMICs: tackling challenges ahead.
    Lancet. 2021;398:489-490.
    PubMed    


  7. KHOO EM, Li D, Ungan M, Jordan R, et al
    Lung health in LMICs: tackling challenges ahead.
    Lancet. 2021;398:488-489.
    PubMed    


    July 2021
  8. TEUFEL F, Seiglie JA, Geldsetzer P, Theilmann M, et al
    Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults.
    Lancet. 2021;398:238-248.
    PubMed     Abstract available


  9. WANG L, Zhou B, Zhao Z, Yang L, et al
    Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18.
    Lancet. 2021;398:53-63.
    PubMed     Abstract available


  10. FLEGAL KM
    BMI and obesity trends in Chinese national survey data.
    Lancet. 2021;398:5-7.
    PubMed    


  11. SALAH RO, Ghandour R, Husseini A
    Prevalence of overweight, obesity, and associated factors among adolescents in the occupied Palestinian territory: a cross-sectional study.
    Lancet. 2021;398 Suppl 1:S46.
    PubMed     Abstract available


    June 2021
  12. TREASURE J, Ambwani S
    Addressing weight stigma and anti-obesity rhetoric in policy changes to prevent eating disorders.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01109.
    PubMed    


    May 2021
  13. ENEBO LB, Berthelsen KK, Kankam M, Lund MT, et al
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.
    Lancet. 2021;397:1736-1748.
    PubMed     Abstract available


  14. SYN NL, Cummings DE, Wang LZ, Lin DJ, et al
    Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.
    Lancet. 2021 May 6. pii: S0140-6736(21)00591.
    PubMed     Abstract available


    April 2021
  15. BECERRIL S, Fruhbeck G
    Cagrilintide plus semaglutide for obesity management.
    Lancet. 2021 Apr 22. pii: S0140-6736(21)00944.
    PubMed    


    March 2021
  16. LATINI R, Staszewsky L
    Semaglutide and effective weight control.
    Lancet. 2021;397:942-943.
    PubMed    


  17. DAVIES M, Faerch L, Jeppesen OK, Pakseresht A, et al
    Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Lancet. 2021 Mar 2. pii: S0140-6736(21)00213.
    PubMed     Abstract available


    November 2020
  18. CHAN JCN, Lim LL, Wareham NJ, Shaw JE, et al
    The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32374.
    PubMed    


    September 2020
  19. HAWKES C, Ruel M, Wells JC, Popkin BM, et al
    The double burden of malnutrition-further perspective - Authors' reply.
    Lancet. 2020;396:815-816.
    PubMed    


  20. STEWART CP, de Pee S, Maleta K, Michaelsen KF, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:814-815.
    PubMed    


  21. OSENDARP SJM, Brown KH, Neufeld LM, Udomkesmalee E, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:813.
    PubMed    


  22. HOSSAIN MS, Ferdous S, Raheem E, Siddiqee MH, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:813-814.
    PubMed    


    May 2020
  23. KASS DA, Duggal P, Cingolani O
    Obesity could shift severe COVID-19 disease to younger ages.
    Lancet. 2020 May 4. pii: S0140-6736(20)31024.
    PubMed    


    January 2020
  24. WILLIAMS R, Aithal G, Alexander GJ, Allison M, et al
    Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK.
    Lancet. 2020;395:226-239.
    PubMed     Abstract available


    December 2019
  25. WELLS JC, Sawaya AL, Wibaek R, Mwangome M, et al
    The double burden of malnutrition: aetiological pathways and consequences for health.
    Lancet. 2019 Dec 13. pii: S0140-6736(19)32472.
    PubMed     Abstract available


  26. HAWKES C, Ruel MT, Salm L, Sinclair B, et al
    Double-duty actions: seizing programme and policy opportunities to address malnutrition in all its forms.
    Lancet. 2019 Dec 13. pii: S0140-6736(19)32506.
    PubMed     Abstract available


  27. POPKIN BM, Corvalan C, Grummer-Strawn LM
    Dynamics of the double burden of malnutrition and the changing nutrition reality.
    Lancet. 2019 Dec 13. pii: S0140-6736(19)32497.
    PubMed     Abstract available


  28. NUGENT R, Levin C, Hale J, Hutchinson B, et al
    Economic effects of the double burden of malnutrition.
    Lancet. 2019 Dec 13. pii: S0140-6736(19)32473.
    PubMed     Abstract available


    October 2019
  29. MUSELLA M, Vitiello A
    The YOMEGA non-inferiority trial.
    Lancet. 2019;394:1412.
    PubMed    


  30. ROBERT M, Maucort-Boulch D, Delaunay D, Disse E, et al
    The YOMEGA non-inferiority trial - Authors' reply.
    Lancet. 2019;394:1412-1413.
    PubMed    


  31. BERGEAT D, Sulpice L, Meunier B, Boudjema K, et al
    The YOMEGA non-inferiority trial.
    Lancet. 2019;394:1411-1412.
    PubMed    


  32. EL FARA H
    The YOMEGA non-inferiority trial.
    Lancet. 2019;394:1411.
    PubMed    


  33. THE LANCET
    Child nutrition: the need for courageous action.
    Lancet. 2019;394:1387.
    PubMed    


  34. MYTTON OT, Fenton-Glynn C, Pawson E, Viner RM, et al
    Protecting children's rights: why governments must be bold to tackle childhood obesity.
    Lancet. 2019 Oct 10. pii: S0140-6736(19)32274.
    PubMed    


  35. XIAO Y, Sun L
    Semaglutide in weight management.
    Lancet. 2019;394:1226.
    PubMed    


  36. WILDING JPH
    Semaglutide in weight management - Author's reply.
    Lancet. 2019;394:1226-1227.
    PubMed    


    August 2019

  37. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31709.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Obesity is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: